The Alzheimer’s disease drug development landscape
Abstract Background Alzheimer’s disease (AD) is a devastating neurodegenerative disease leading to dementia. The field has made significant progress over the last 15 years. AD diagnosis has shifted from syndromal, based on signs and symptoms, to a biomarker construct based on the pathological hallma...
Main Authors: | Pieter van Bokhoven, Arno de Wilde, Lisa Vermunt, Prisca S. Leferink, Sasja Heetveld, Jeffrey Cummings, Philip Scheltens, Everard G. B. Vijverberg |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-11-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-021-00927-z |
Similar Items
-
The “rights” of precision drug development for Alzheimer’s disease
by: Jeffrey Cummings, et al.
Published: (2019-08-01) -
Emerging drugs and targets for Alzheimer's disease /
by: Martn̕ez, Ana, 1961-, et al.
Published: (c201) -
Open drug discovery in Alzheimer's disease
by: Alison D. Axtman, et al.
Published: (2023-04-01) -
Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis
by: Anna Sampietro, et al.
Published: (2022-04-01) -
AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery
by: Frances M. Potjewyd, et al.
Published: (2022-01-01)